A first of its kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity is being discovered by researchers.
The compounds, known as ribonucleoside analogs 8-azaadenosine, formycin A, 3-deazauridine, 5-fluorocytidine and 2'-C-methylcytidine, were found to stop the replication and spread of HIV by blocking HIV DNA synthesis or by inducing lethal mutagenesis. Lethal mutagenesis annihilates HIV by causing it to mutate to the point of extinction.
AIDS/HIV - Prevention And Transmission
Encyclopedia section of medindia explains in brief about the prevention for AIDS/HIV
Advertisement
The compound 3-deazauridine stopped HIV by creating so many mutations in the virus that the virus was no longer able to spread throughout the body by infecting other cells.
The other compounds caused early termination of HIV DNA synthesis, again preventing the virus from being able to reproduce.
University of Minnesota virologist Louis Mansky, Ph.D, said that these ribonucleoside analogs were not generally thought to be associated with affecting HIV DNA synthesis - a critical step in virus replication, asserting that they don't yet know all the details for how these particular compounds stop the virus in its path.
![AIDS/HIV - Clinical Features]( "AIDS/HIV - Clinical Features")
Encyclopedia section of medindia gives general info about HIV Clinical Features
The research, if translatable, will provide a potentially cost-effective and fresh treatment option to counter HIV's rapid evolution and treat HIV resistance to currently approved anti-HIV drugs. Anti-HIV ribonucleoside analogs are less expensive to create in a laboratory than deoxyribonucleoside analogs, which are key in drugs currently used to stop HIV replication and cell spread.
Additionally, the similarity of ribonucleoside analogs to deoxyribonucleosides may help speed up the development process to make full use of this target as a wealth of understanding around ribonucleoside analogs already exists.
The findings have been published in the Journal of Virology.
Source: ANI
University of Minnesota virologist Louis Mansky, Ph.D, said that these ribonucleoside analogs were not generally thought to be associated with affecting HIV DNA synthesis - a critical step in virus replication, asserting that they don't yet know all the details for how these particular compounds stop the virus in its path.
AIDS/HIV - Clinical Features
Encyclopedia section of medindia gives general info about HIV Clinical Features
Advertisement
The research, if translatable, will provide a potentially cost-effective and fresh treatment option to counter HIV's rapid evolution and treat HIV resistance to currently approved anti-HIV drugs. Anti-HIV ribonucleoside analogs are less expensive to create in a laboratory than deoxyribonucleoside analogs, which are key in drugs currently used to stop HIV replication and cell spread.
Additionally, the similarity of ribonucleoside analogs to deoxyribonucleosides may help speed up the development process to make full use of this target as a wealth of understanding around ribonucleoside analogs already exists.
The findings have been published in the Journal of Virology.
Source: ANI
AIDS and Pregnancy
The Acquired immune deficiency syndrome is brought about by the deadly human immunodeficiency virus. In the USA alone an estimate of 120,000 - 160,000 women are HIV- infected.
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Research News
Autoimmune disorders were found to be linked to Sjogren's, systemic lupus erythematosus, and systemic sclerosis.
Successful brain pacemaker implantation has helped a 51year old Parkinson's disease patient to revitalize her quality of life.
Recent recommendations on lifestyle behaviors to prevent progression of rheumatic and musculoskeletal diseases revealed.
The study offers insights into how psoriasis can trigger diabetes, heart disease, and inflammatory bowel disease.
Utilizing microparticles for therapy could mark a significant milestone in the fight against multiple sclerosis (MS) and other autoimmune diseases.